MetaCap

Anavex Life Sciences (AVXL) vs Eloxx Pharmaceuticals (ELOX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Anavex Life Sciences is the larger company by market cap ($54.8 million vs $43.7 million), about 1.3 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AVXL-76.71%ELOX-2.91%
+99%+7%-85%
Jun 9, 20261 yearNov 20, 2026
AVXL-76.34%ELOX-20.93%
+62%-11%-83%
Jun 8, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AVXL versus ELOX key metrics
MetricAVXLELOX
Share price$0.5915$10.69
Market cap$54.83M$43.69M
1-day change-11.39%-1.75%
YTD return-83.38%—
1-year return-81.86%—
5-year return-96.96%—
P/E ratio (TTM)—5.63
EPS (TTM)$-0.14$1.90
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Revenue growth (YoY)—-100.00%
Net income (latest FY)$-46.38M$-6.00M
52-week high$5.36$23.40
52-week low$0.59$8.20
Distance from 52-week high-88.96%-54.32%
Analyst consensusnonenone
Avg. price target upside—+257.81%
Average volume1.15M28.48K
Shares outstanding92.70M4.09M
Employees3410
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Anavex Life Sciences

AVXL stock →

Anavex Life Sciences Corp. operates as a biopharmaceutical company.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 34 employees

About Eloxx Pharmaceuticals

ELOX stock →

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 10 employees

AVXL vs ELOX FAQ

Which is bigger, Anavex Life Sciences or Eloxx Pharmaceuticals?

Anavex Life Sciences (AVXL) is larger, with a market capitalization of $54.83M compared with $43.69M for Eloxx Pharmaceuticals (ELOX).

Are Anavex Life Sciences and Eloxx Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons